A randomized, double‐blind, placebo‐controlled, dose‐escalating phase IIa trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of multiple oral doses of Pynegabine tablets as add‐on therapy in patients with focal epilepsy
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.70002 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Shan Wei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Epilepsies, Partial, Anticonvulsants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Nova Program, Capital Health Research and Development of Special grants, Beijing Postdoctoral Science Foundation.
Abstract (Originalsprache)
Aims
This study aims to investigate the safety, tolerability, efficacy, and pharmacokinetics of Pynegabine as an add‐on therapy in the treatment of focal epilepsy. Methodology This is a protocol phase‐IIa, randomized, double‐blinded, placebo‐controlled, multicenter study in patients with focal epilepsy from multiple centers in China who have been treated with at least 2 ASMs without effective control. The study involves an 8‐week run‐in period with stable use of previous medications. Patients are then randomized to receive either Pynegabine or a placebo. Sentinel administration is performed initially, and subsequent patients are randomized based on safety assessments. Three dose cohorts (15, 20, and 25 mg/d) are established. Efficacy is assessed through various measures, including seizure frequency, CGI score, PGI score, HAMA score, HAMD score, MoCA scale score, QOLIE‐31 scale score, and 12 h‐EEG score. Safety evaluations, PK blood samples, concomitant medications, and adverse events are also recorded.
Conclusion
Data from the study will be used to evaluate the safety, tolerability, efficacy, and pharmacokinetics of Pynegabine tablets as add‐on therapy for focal epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- China National Clinical Research Center for Neurological Diseases, Beijing, China.
- Beijing Institute for Brain Disorders, Beijing, China.
- Sanbo Brain Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Weng Shiwen, Wang Qun
Förderung
- Beijing Nova Program
- Capital Health Research and Development of Special grants
- Beijing Postdoctoral Science Foundation
- National Natural Science Foundation of China
- National Key R and D Program of China grant
Zitieren
APA
Wei, S., Shiwen, W., Cao-Wenjing, C., Huajun, Y., & Qun, W. (2024). A randomized, double‐blind, placebo‐controlled, dose‐escalating phase IIa trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of multiple oral doses of Pynegabine tablets as add‐on therapy in patients with focal epilepsy. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70002
Vancouver
Wei S, Shiwen W, Cao-Wenjing C, Huajun Y, Qun W. A randomized, double‐blind, placebo‐controlled, dose‐escalating phase IIa trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of multiple oral doses of Pynegabine tablets as add‐on therapy in patients with focal epilepsy. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.70002
BibTeX
@article{Wei2024,
author = {Wei, Shan and Shiwen, Weng and Cao-Wenjing, Chang and Huajun, Yang and Qun, Wang},
title = {A randomized, double‐blind, placebo‐controlled, dose‐escalating phase IIa trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of multiple oral doses of Pynegabine tablets as add‐on therapy in patients with focal epilepsy},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.70002}
}
EUVIMED